Extended thromboprophylaxis after hip or knee replacement.

Area of Science:

• Orthopedic Surgery
• Vascular Medicine
• Pharmacology

Background:

• Early hospital discharge following total joint arthroplasty necessitates extended outpatient thromboprophylaxis.
• Existing research includes multiple clinical trials and meta-analyses on various thromboprophylactic agents and regimens.

Purpose of the Study:

• To evaluate the efficacy and safety of extended outpatient thromboprophylaxis after total joint arthroplasty.
• To determine optimal duration and agent for preventing venous thromboembolism (VTE) in this patient population.

Main Methods:

• Systematic review and meta-analysis of controlled clinical trials.
• Analysis of data comparing different anticoagulation agents and durations.
• Assessment of outcomes including VTE events and major bleeding.

Main Results:

• Extended prophylaxis with low-molecular-weight heparin (LMWH) significantly reduces VTE episodes after knee or hip arthroplasty.
• No significant increase in major bleeding complications was observed with LMWH.
• >98% of patients receiving long-term LMWH prophylaxis remained free from symptomatic deep venous thrombosis and pulmonary embolism.

Conclusions:

• Extended prophylaxis with LMWH for 4 weeks post-surgery is a safe and cost-effective strategy.
• Consideration of once-daily LMWH for 4 weeks is recommended for patients undergoing total joint arthroplasty to minimize risk.